Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01170962




Registration number
NCT01170962
Ethics application status
Date submitted
16/07/2010
Date registered
28/07/2010
Date last updated
12/10/2015

Titles & IDs
Public title
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
Scientific title
A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy
Secondary ID [1] 0 0
2010-019378-34
Secondary ID [2] 0 0
AI444-011
Universal Trial Number (UTN)
Trial acronym
HEPCAT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C Virus 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BMS-790052
Treatment: Drugs - BMS-790052
Treatment: Drugs - Placebo
Treatment: Drugs - peginterferon alfa-2a
Treatment: Drugs - ribavirin

Experimental: Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior null responders)

Experimental: Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior null responders)

Experimental: Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior partial responders)

Experimental: Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior partial responders)

Experimental: Arm 5: Placebo plus peginterferon alfa-2a and ribavirin - (prior partial responders only)


Treatment: Drugs: BMS-790052
Film coated tablet, Oral, 20 mg, once daily, 24 weeks

Treatment: Drugs: BMS-790052
Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks

Treatment: Drugs: Placebo
Film coated tablet, Oral, 0mg, Once daily, 24 weeks

Treatment: Drugs: peginterferon alfa-2a
Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks

Treatment: Drugs: ribavirin
Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Extended Rapid Virologic Response (eRVR)
Timepoint [1] 0 0
Week 4, Week 12
Primary outcome [2] 0 0
Percentage of Participants With 24-week Sustained Virologic Response (SVR24)
Timepoint [2] 0 0
Follow-up Week 24
Primary outcome [3] 0 0
Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died On-treatment
Timepoint [3] 0 0
From first dose to last dose plus 7 days, up to 49 weeks
Primary outcome [4] 0 0
Number of Participants With Serious Adverse Events (SAEs) and Who Died During Follow-up Period
Timepoint [4] 0 0
From day 8 post last dose of treatment up-to Week 72
Secondary outcome [1] 0 0
Percentage of Participants With Rapid Virologic Response (RVR)
Timepoint [1] 0 0
Week 4
Secondary outcome [2] 0 0
Percentage of Participants With Complete Early Virologic Response (cEVR)
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)
Timepoint [3] 0 0
Follow-up Week 12
Secondary outcome [4] 0 0
Number of Participants With Genotypic-1A Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
Timepoint [4] 0 0
Baseline to follow-up Week 48
Secondary outcome [5] 0 0
Number of Participants With Genotypic-1B Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
Timepoint [5] 0 0
Baseline to follow-up Week 48

Eligibility
Key inclusion criteria
* Subjects chronically infected with HCV genotype 1
* Non-responder to prior therapy with peginterferon alfa and ribavirin
* HCV RNA viral load of 100,00 IU/mL
* Results of a liver biopsy = 24 months prior to randomization consistent with chronic HCV infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study population)
* Ultrasound, CT scan or MRI results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma
* Body Mass Index (BMI) of 18 to 35 kg/m2
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Positive for Hepatitis B infection (HBsAg) or HIV-1/HIV-2 antibody at screening
* Evidence of medical condition associated with chronic liver disease other than HCV
* Evidence of decompensated cirrhosis based on radiologic criteria or biopsy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2012
Sample size
Target
Accrual to date
Final
512
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - Randwick
Recruitment hospital [2] 0 0
Local Institution - Clayton
Recruitment hospital [3] 0 0
Local Institution - Heidelberg
Recruitment hospital [4] 0 0
Local Institution - Prahan
Recruitment hospital [5] 0 0
Local Institution - Fremantle
Recruitment hospital [6] 0 0
Local Institution - Perth
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3004 - Prahan
Recruitment postcode(s) [5] 0 0
6160 - Fremantle
Recruitment postcode(s) [6] 0 0
6001 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Wisconsin
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Santa Fe
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
British Columbia
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Denmark
State/province [25] 0 0
Aarhus
Country [26] 0 0
Denmark
State/province [26] 0 0
Hvidovre
Country [27] 0 0
Denmark
State/province [27] 0 0
Odense
Country [28] 0 0
France
State/province [28] 0 0
Clichy Cedex
Country [29] 0 0
France
State/province [29] 0 0
Creteil Cedex
Country [30] 0 0
France
State/province [30] 0 0
Lyon Cedex 04
Country [31] 0 0
France
State/province [31] 0 0
Nice Cedex 03
Country [32] 0 0
France
State/province [32] 0 0
Paris Cedex 14
Country [33] 0 0
France
State/province [33] 0 0
Paris Cedex
Country [34] 0 0
France
State/province [34] 0 0
Vandoeuvre Les Nancy
Country [35] 0 0
Germany
State/province [35] 0 0
Essen
Country [36] 0 0
Germany
State/province [36] 0 0
Frankfurt
Country [37] 0 0
Germany
State/province [37] 0 0
Hamburg
Country [38] 0 0
Germany
State/province [38] 0 0
Hannover
Country [39] 0 0
Italy
State/province [39] 0 0
Cisanello (pisa)
Country [40] 0 0
Italy
State/province [40] 0 0
Pavia
Country [41] 0 0
Mexico
State/province [41] 0 0
Jalisco
Country [42] 0 0
Mexico
State/province [42] 0 0
Morelos
Country [43] 0 0
Mexico
State/province [43] 0 0
Nuevo Leon
Country [44] 0 0
Puerto Rico
State/province [44] 0 0
Ponce
Country [45] 0 0
Puerto Rico
State/province [45] 0 0
San Juan
Country [46] 0 0
Sweden
State/province [46] 0 0
Gothenburg
Country [47] 0 0
Sweden
State/province [47] 0 0
Stockholm

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.
Trial website
https://clinicaltrials.gov/study/NCT01170962
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01170962